

May 25, 2009

To whom it may concern

NanoCarrier Co., Ltd.  
Ichiro Nakatomi, Ph.D., President & CEO  
(Code No.; 4571 Tokyo Stock Exchange Mothers)  
Toshiki Kaura, Head of President's Office  
TEL. +81-3-3548-0217

**Signing of Exclusive Licensing Agreement Concerning Cationic Polyamino Acids  
with The University of Tokyo and TODAI TLO, Ltd.**

We are pleased to announce that NanoCarrier and “The University of Tokyo and TODAI TLO” (TODAI TLO) signed the licensing agreement of the patent, of which TODAI TLO has the right to grant license of use. In the agreement TODAI TLO grants NanoCarrier the right of exclusive use with the right of re-granting the patent in Japan and in foreign countries NanoCarrier desires.

This invention constitutes new substances of cationic polyamino acids and technologies for forming macromolecular ionic complex with small molecular nucleic acids such as siRNA. This technology enables nucleic acids to be brought into the cells of lesions in the form of endoplasmic reticulum called endosome and to be released into cytoplasm to express activities.

This technology enables siRNA medicines to express better efficacy with lower toxicities compared with those by existing technologies. We can facilitate with this licensing agreement and R&D activities of siRNA medicines for cancers, inflammatory diseases, liver diseases and etc.

Explanation of Technical Terms

Cationic polyamino acids:  
i.e., positively charged polyamino acid complexes

Macromolecular ionic complex:  
i.e., Complex formed by the bonding of positively charged macromolecules with negatively charged macromolecules

siRNA<sup>‡</sup> small interfering RNA  
Interfering low-polymer RNA. It is capable of suppressing biosynthesis of certain disease-related proteins in the cell. Since siRNA is extremely unstable a delivery technique capable of guiding the drug into the cell is seen as important.